Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer

Summary

This is a phase II trial designed to estimate the activity of single agent tremelimumab in subjects with metastatic urothelial cancer with disease progression despite prior treatment with PD-1/PD-L1 blockade. The primary endpoint is objective response rate and the study will employ a Simon's 2-stage design.

Timeline

Start

2018-11-12

Primary completion

2021-12-06

Completion

2023-06-07

Publications

• Miller EJ, Rose TL, Maughan BL, Milowsky MI, Bilen MA, Carthon BC, Gao X, Rapisuwon S, Zhao Q, Yu M, Agarwal N, Galsky MD. Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockade. Cancer. 2024 May 1;130(9):1642-1649. doi: 10.1002/cncr.35179. Epub 2024 Jan 5.

Drugs

Indications